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INTRODUCTION
Pregnancy induces progressive changes in maternal carbohydrate metabolism. As 
pregnancy advances insulin resistance and diabetogenic stress due to placental hormones 
necessitate  compensatory  increase  in  insulin  secretion.  When  this  compensation  is 
inadequate  GDM develops.  Magnitude  of  complications  are  equal  in  GDM than  in 
women with pre GDM.
Universal  Screening  is  strongly  recommended  for  the  population  ethnically 
proven to high prevalence of type 2DM. In much of the world, GDM is diagnosed if 2 
hrs Blood glucose ≥ 140 mg/dl.   GDM woman has increased incidence of caesarian 
section, pre eclampsia and macrosomia.
A short term intensive care not only results in the safe motherhood but also gives 
a long term pay off in the primary prevention of obesity, IGT, and diabetes in the off 
spring as the “Preventive Measures Starts in Intrauterine Life”.
Metabolic adaptations that occur during pregnancy are to accommodate a rapidly 
growing  tissue  transplant,  the  conceptus.  The  conceptus  brings  about  alterations  in 
maternal fuel metabolism and hormones.
Fuel metabolism in normal pregnancy
In non GDM pregnancy:
 Facilitated insulin action during the first half of pregnancy
 Diabetogenic stress during the second half of pregnancy
In early weeks of pregnancy
 Increased insulin fasting concentration
 Increased glucose stimulated insulin release (Peak 18-20 wks) 
 Increased estrogen and progesterone which induces Beta cell hyperplasia.
Finally  ends in  hyperinsulinemia,  insulin  being anabolic  and anti  catabolic  hormone 
favours:
 Tissue glycogen storage
 Peripheral glucose utilization from liver
 Needs to reduce FBS by 10%
Later weeks of gestation
Increase in Human placental lactogen, Prolactin and Cortisol leads to diabetogenic 
stress. Due to this, maternal insulin sensitivity reduces by 50%, metabolic alterations 
under influence of insulin and placental hormones facilitates anabolism during feeding 
and accelerated catabolism during fasting.
Fasting glucose is constantly low due to constant intake of glucose by the fetus. 
Low FBG due to deficient glucogenic amino acid alanine and glycine called “substrate 
deficiency syndrome”.
In second half of the pregnancy insulin resistance and diabetogenic stress due to 
placental hormones necessitate compensatory increase in insulin secretion, GDM occurs 
when this compensation is inadequate.
Etiological classification of diabetes mellitus:
Type 1A: Immune mediated β cell destruction.
Type 1B: Idiopathic β cell destruction
Type 2: May range predominantly insulin resistance to 
predominantly insulin secretory  defect with insulin resistance.
Genetic Defect in β cell function:
Genetic syndrome - Downs, klienfelter syndrome, turner Syndrome.
Exocrine pancreas - Pancreatitis, cystic fibrosis.
Endocrinopathies - Cushing syndrome, pheochromocytoma, and 
others.
Drugs                     -       β agonist, thiazides.
Infections - congenital Rubella, CMV, Cocksackie  
Classification of diabetes complicating pregnancy
Onset FBG 2 hrs PPG Therapy
A1 Gestational < 95 mg/dl < 120 mg/dl Diet 
A2 Gestational > 95 mg/dl > 120 mg/dl Insulin
Class
B
C
D
F
R
H
Age of onset 
Over 20 yrs
10-19 yrs
< 10 yrs
Any
Any
Any
Duration
< 10 yrs
10-19 yrs
> 20 yrs
Any
Any
Any
Vascular disease
None
None
B. Retinopathy
Nephropathy
Pro. Retinopathy
Heart 
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Maternal Metabolic changes during pregnancy in GDM
1. Reduced fasting plasma glucose level
2. Increased fasting and post prandial plasma insulin levels
3. Increased PPBS glucose levels
4. β cell hypertrophy and hyperplasia 
5. Reduced insulin sensitivity and increased lipolysis
Pathogenesis
Increased maternal age and obesity are significant contributing genetic factors. In 
about 20% of GDM patients sluggish early insulin secretion cannot be demonstrated, 
due to increased elaboration / heightened / sensitivity to one or more of the gestational 
counter hormones
Post receptor defect in the insulin signaling cascade appears to be a cause for the 
reduced  insulin  sensitivity  in  pregnant  women  with  normal  glucose  tolerance  and 
gestational diabetes.
 IR substrate (IRS-1) expression is reduced in all pregnant women compared to 
non  pregnant  controls,  this  down  regulation  is  due  to  cytokine  tumour  necrosis 
factor.Simply  the  pathophysiology  of  GDM  has  been  related  to  excessive  insulin 
antagonism by the pregnancy contrainsulin factors
When maternal insulinogenic compensation is inadequate to offset these factors, 
gestational diabetes will supervene. Reduced β cell function that occurs in GDM women 
may be the indication for the future susceptability to diabetes.
Consequences on fetus:
1)  Consequences of metabolic changes revolve around maternal hyperglycemia and 
fetal hyperinsulinemia. Glucose traverse the placenta by facilitated diffusion and 
amino acid by active transport and enter the fetal circulation. Placental glucose 
transport is dependent on the glucose transporter (GLUT) family and GLUT- 1 is 
the principal transporter.
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With  increase  in  gestational  age,  2-3  fold  increase  in  expression  of 
syntiotrophoblast glucose transportation occurs, aminoacid by active transport. All this 
are regulated by insulin, any disturbance in the secretion and action of insulin influence 
the whole nutrient composition of the fetus and fetal hyper insulinemia.
Maternal abnormal mixture of nutrients gain access to the developing fetus and 
modify  phenotype  gene  expression  in  newly  forming  cells  with  thereby  causing 
permanent short and long term effects in the offspring.
Fetal problems associated with Maternal hyperglycemia:
First Trimester Second Trimester Neonatal 
Malformations
Growth 
Retardation
Fetal Wastage
Hypertrophic 
Cardiomyopathy
Polyhydramnios
Erythraemia
Placental 
insufficiency
Hypoglycemia
Hypocalcaemia 
Hyperbilirubinemia
Respiratory Distress
Macrosomia > 4 kg
preeclampsia
Fetal loss
Hypomagnesemia
Low IQ
The mechanism suggestive of  the teratogenic  effect  in  early  post  implantation 
stage  of  the  embryo,  affecting  the  normal  functioning  yolk  sac  which  regulates  the 
nutrient  transport  from  maternal  plasma  to  embryo  during  early  neural  tube 
development. 
Oxidative metabolism and generation of free oxygen radicals that may be toxic to 
the embryo.  Glucose induces mutation in embroyonic DNA.
Hence excellent control of maternal metabolism commence before conception and 
must be maintained during first 8 weeks.  Supplementing with folic acid, antioxidants 
play role in preventing malformations from 7.5 to 0.8%.
Definition: GDM is defined as carbohydrate intolerance of variable severity with onset 
or first  recognisation during present  pregnancy, includes the glucose intolerance that 
may have ante dated the present pregnancy. 
GDM is due to sluggish first phase insulin release and also due to effect of anti 
insulin hormones for glucose utilization, insulin secretion in pregnancy.
Insulin Secretion in GDM and Non GDM
GDM Non GDM
Insulin secretion ↑ ↑
Glucose stimulated Insulin Secretion ↑ ↑↑
Peak Plasma insulin Late N
1st phase insulin - More
2nd phase insulin Same Same
Woman with normal glucose tolerance increases her insulin secretion over and 
above the insulin resistance, maintains glycemic level, do not develop GDM. 30% GDM 
women will progress to type 2 DM in 2-20 years after pregnancy.
Etiology and Pathogenesis:
1. Auto immune destruction of β cells 
2. Impaired β - cell function
3. Increased insulin degradation
4. Decreased tissue sensitivity to insulin
a. Impaired insulin – insulin receptor binding
b. Impaired intracellular insulin signaling 
Effect  of  maternal  fuels  on  fetal  development:  The  hyperglycemia  – 
hyperinsulinism hypothesis of Pedersen has been modified to include contributions of 
other maternal fuels besides glucose that are also responsive to maternal insulin.  All of 
these  can  influence  the  growth  of  the  fetus  and  the  augmentation  of  fetal  insulin 
secretion.  Within this formulation, growth will be disproportionately greater in insulin-
sensitive than in insulin – insensitive tissues on the fetus. “Indian women have 11 fold 
increased risk of developing GDM compared to White women.”
Indicators for screening:
High risk Low risk
1)  Age > 25 years - Age < 25 years
2) IUD / anomaly - Low ethnic group
3) Recurrent pregnancy loss - No family history of DM
4) Family history of DM - BMI – normal
5) Macrosomia - Good obstetric output
6) Obese women
7) PIH
8) Polyhydramnios
9) Twin pregnancy
Screening:
Urine glucose:
During pregnancy renal threshold for glucose is lowered.  It renders glycosuria 
less specific for detection of GDM hence not recommended as screening test.
Blood glucose:
The usual recommendation for screening is between 24 and 28 weeks of gestation. 
The recent concept is that all pregnant women should undergo glucose tolerance test in 
the 1st trimester itself. If negative, repeat test around 24 to 28 weeks and 32 to 34 weeks.
ADA Recommendation:
1. One Step Procedure: 
Diagnostic  100  gm  oral  glucose  tolerance  test  without  prior  serum  glucose 
screening.
2. Two Step Approach:
 Initial  screening by 50 gm oral  glucose and if  Blood Glucose > 140 mg% 
patient  is  asked  for  diagnostic  OGTT,  this  method  identifies  upto  80% of 
GDM.
      3. Carpenter and Coustan diagnostic criteria:
The American Diabetes Association has adopted Carpenter and Coustan criteria.
Time 100 g OGTT 75 g OGTT (sacht’s 
criteria)
Fasting 95 mg/dl 95 mg/dl
1 hr 180 mg/dl 180 mg/dl
2 hr 155 mg/dl 155 mg/dl
3 hr 140 mg/dl
Two  or  more  of  the  venous  plasma  concentrations  must  be  met  or  exceeded  for  a 
positive diagnosis.
WHO Criteria
A standard OGTT should be performed after over night fasting by giving 75 g of 
glucose.  Plasma glucose is measured at fasting and after 2 hours.  Pregnant women who 
meet WHO criteria for IGT (2 hrs PG > 140 mg/dl) are classified as having gestational 
diabetes mellitus (GDM).
FPG 2 hrs PG
IGT < 126 mg/dl 140-200 mg/dl
Diabetes > 126 mg/dl > 200 mg/dl
If fasting plasma glucose is more than 126 mg and / or 2 hr post glucose more 
than 200 mg probably she has been having undetected diabetes prior to conception and 
can be confirmed by HbA1c estimation.
Glycosylated Hemoglobin (HbA1c)
HbA1c is not suitable for screening for gestational diabetes, since it yields false 
positive results in 41% and false negative in 26%.  HbA1c estimation is useful in pre-
gestational  diabetes  to  know the  retrospective  blood  glucose  control  at  the  time  of 
conception.
Serum Fructosamine:
Like  HbA1c serum Fructosamine  is  not  a  useful  screening  test  for  gestational 
diabetes.  This test is useful to assess the short-term state of maternal glucose control 
during the past two weeks.
Selective screening leaves 45.4 % of pregnant woman unscreened, out of which 
35% has GDM. Uniform policy of adopting WHO screening and diagnostic criteria is 
recommended for the following reasons.
1. GDM diagnosis based on two hours 75 gm OGTT defined either WHO or ADA 
predicts further development of DM in mother.
2. Criteria recommended by WHO is simple and cost effective and is practiced in 
many centers.
3. Further assuring that effective treatment is available, WHO criteria of 2 hrs PPGS 
> 140 mg /  dl  identify  large  number  of  cases  may  have greater  potential  for 
prevention.
4. One step procedure is both diagnostic and screening.
Management:
The important predictor of fetal outcome either in pre gestational or Gestational 
diabetes is the glycemic control attained immediately before and during pregnancy.  The 
plasma  glucose  level  of  normal  pregnant  women  is  less  than  90  and  120  mg% 
respectively during fasting and non-fasting states.  Hence the best fetal outcome can be 
expected by maintaining the mean plasma glucose level around 105 mg.
Practical self management skills are essential for attaining good glycemic control 
in preparation for pregnancy and during pregnancy.
1. Appropriate meal plan.
2. Self monitoring of blood glucose. (SMBG)
3. Self administration of insulin and adjustment of insulin doses.
4. Treatment of hypoglycemia (family members and patient).
5. Safe physical activity.
6. Development of techniques to reduce stress.
A. Medical Nutrition Therapy (MNT)
All women with GDM should receive nutritional counseling.  The meal pattern 
should provide adequate  calories and nutrients  to meet  the needs of pregnancy.  The 
expected weight gain during pregnancy is 300 to 400 gm/week and total weight gain is 
10 to 12 kg by term.  Approximately  30  to  40  kcal/kg  ideal  body  weight  or  an 
increment of 30 kcal/day above the basal requirement is needed. Pregnancy is not the 
ideal time for obesity correction.
As a part  of the MNT, pregnant woman are advised to wisely distribute their 
calorie consumption especially the breakfast into two equal halves and consuming the 
portions with a two hour gap in between. MNT is suggested for 2 weeks.
B. Insulin Treatment
Insulin is essential if MNT fails to achieve euglycemia.  In normal pregnancy, the 
FBG concentration ranges between 55 and 70 mg/dl, the 1 hr PPBS level is < 120 mg/dl.
SMBG is to be performed before breakfast and 2½ hrs after each meal.  GDM 
women usually have high post breakfast plasma glucose level compared to post lunch 
and post dinner.  A few GDM women do have post dinner plasma glucose also high. 
Insulin is started within 1 to 2 weeks, if FBS is more than 90 mg/dl even after MNT.
Peaking of plasma glucose is  high with breakfast  (due to dawn phenomenon). 
Plasma glucose value is 12% higher than whole blood value. If FPG concentration on 
OGTT is > 120 mg/dl the patient is started with insulin immediately with Meal plan.
In this regimen two third of the total daily dose of insulin is given in the morning 
and one third in the evening.  For each combination one third dose should be regular 
insulin  and  two  third  intermediate  acting  insulin.  With  this  regimen  if  the  patient 
continues to have fasting hyperglycemia, the intermediate acting insulin has to be given 
at bedtime instead of before dinner.
Insulin dose is individualized. Initial dose should be as low as 4 units and adjusted 
later.  The  above  regimen  of  regular  and intermediate  acting  insulin  in  the  morning 
corrects hyperglycemia in most cases.
Inclusion of fetal growth might provide the opportunity to reduce glucose testing 
in low risk pregnancies. Maintenance of mean blood glucose less than 105 mg% is ideal 
for good fetal outcome, this would prevent the newborn from hypoglycemia.
As long as fetus is in the uterine compartment it has enough fuel to maintain its 
blood glucose level.
When fetus is delivered, the supercharged β cells of neonate continue to secrete 
insulin. But there is no fuel supply from the maternal compartment and the new born 
develops hypoglycemia. Neonatal hypoglycemia is due to poor control of diabetes in the 
mother.
Though oral Anti diabetic drugs are not recommended, reports have shown good 
fetal outcome in GDM women – on glyburide (micronised glibenclamide). Metformin 
has been found to be useful in women with polycystic ovarian disease.
Self glucose monitoring is needed once in a week, once target is achieved, once in 
a month FBS and PPBS up to 28 weeks, more than28 wks once in 15 days till 32 weeks, 
then once in a week till delivery.  In high risk cases frequency intensified with SMBG. 
Others include fundus examination, estimation of microalbuminuria.
Obstetrical Management procedures
Procedure
Risk Based on glycemic control, vascular 
disease
Low Risk High Risk
Dating Ultra Sound 8-12 Weeks 8-12 Weeks
Prenatal  Genetic 
Diagnosis
As Needed As Needed
Fetal  Echo 
Cardiography
18-22 Weeks 18-22 Weeks
USG for fetal growth 28 and 37 Weeks Monthly 
Biophysical Profile 36 Weeks, Weekly 27 Weeks, 1-3 /Week
Amniocentesis  for 
lung maturity
- 35 – 38 Weeks
Induction of Labor 40  Weeks 35-38 Weeks
Intra partum Diabetic Management:  Metabolic studies in non GDM women, 
during labour revealed that glucose turn over is increased fourfold with little changes in 
insulin level during active labour, insulin requirement is zero while glucose is required 
at 2.6 mg / kg / min.  Labour should be induced in the morning, IV saline should be used 
as  medium.GDM women does  not  require  insulin  once  labour  begins,  no  insulin  is 
needed after expulsion of placenta.
GDM requires follow up and glucose tolerance test with 75 gm oral glucose test 
after 6 weeks and if necessary repeated after 6 months. GDM recurs approximately in 
50% of subsequent   pregnancies. Maintaining ideal body weight approximately solves 
the risk.
The requirement of insulin in addition to diet, to maintain euglycemia during the 
index pregnancy is also predictive of future diabetes.
The maternal health and fetal outcome depends upon the care by the committed 
team of diabetologist, obstetricians and Neonatalogists.
REVIEW OF LITERATURE
History
Diabetes mellitus was well recognized as medical disorder more than 2000 years 
ago.
1500 BC, Greek Father of Medicine Hippocrates mentioned “making water too 
often”  Aristotle  referred  to  “Wasting  of  the  Body”.  Reference  in  the  ancient  book 
“disease of rich, brought about by gluttony, or over indulgence in flour and sugar.”
Dr. Elliott  Joslin is  rembered as the proston physician who bridged the period 
immediately  before  insulin  discovery  and  the  existing  clinical  demonstration  of  its 
effectiveness in the following decade.
In the pre insulin days, death of mother during and soon after pregnancy from 
uncontrolled DM was the major risk.
O’  Sullivan first  used the term gestational  diabetes  mellitus  in 1961.  GDM is 
defined as the carbohydrate intolerance of varying severity with onset or first recognized 
during pregnancy during the 1st work shop 1980, Chicago.
The  first  prospective  study  of  carbohydrate  metabolism  in  pregnancy  was 
established by Boston 1954, using 50 gm 1 hour screening test.
HG Bennewitz: DM – symptom of pregnancy in 1824 from University of Berlin 
was the first reference to diabetes in pregnancy. “disease appeared along with pregnancy 
at  the  very  same  time,  while  pregnancy  lasted  it  lasted,  it  terminated  soon  after 
pregnancy”.
Norbert Frenikel and Broyd Metzger ensured that the concept of GDM is now 
firmly imprinted on the obstetric mind, major place as an epidemiological tool not only 
on immediate out  come of the pregnancy but  also on the long term effects on both 
mother and baby.
There are several identifiable predisposing risk factors for GDM in the absence of 
risk factors for less incidence of GDM.(1)
Study was performed on 1251 pregnant women, the mean age of these pregnant 
women  is  23-24  years,  16.5% of  them found  to  have  GDM.  Study  concludes  that 
increased prevalence of GDM in our population necessitates the universal screening for 
glucose intolerance in pregnancy.
 Using 2 hour plasma glucose > 140 mg% is simple and economical particularly 
for countries ethnically more prone to high prevalence of diabetes mellitus (2).
GDM was twice as common in the daughters of diabetic mothers 11% than father 
5% (p 0.002).  An excess  of  maternal  transmission of  diabetes  is  consistent  with an 
epigenetic effect of hyperglycemia in pregnancy acting in addition to genetic factors to 
produce diabetes in the next generations (3).
Early  diagnosis  and  treatment  may  result  in  decreased  perinatal  morbidity  in 
women with early diagnosed diabetes requiring higher insulin dose than lately diagnosed 
GDM (4).
Comparative  study  of  2  routine  screening  strategies  for  gestational  diabetes 
mellitus concludes universal screening seems to be most appropriate routine screening 
strategy, because it is difficult to know exactly the specific risk factors of a population to 
do selective screening (5).
With high prevalence of diabetes, high proportion of patient potential to develop 
GDM is  identified  with  a  selective  screening  in  this  study.  Universal  screening  for 
GDM, the best  way to  identify  patient  and prevent  adverse  obstetrical  and neonatal 
outcome (6).
GDM was significantly higher and correlated in women with positive history of 
diabetes, increasing age then previous pregnancies, prepregnancy overweight and short 
stature (7).
GDM is a transient  abnormality of glucose intolerance during pregnancy. It  is 
variously estimated that 3-5% of pregnancies are complicated by diabetes 1-6% develop 
significant hyperglycemia during pregnancy to meet criteria for diagnosis of diabetes. 
20-50% of women with GDM develop type 2 diabetes mellitus.
More controversial in the diagnosis of GDM.  Coustan succinately summarized 
the issues surrounding the diagnosis of GDM by posing the four key questions,
1. What level of maternal hyperglycemia worsens the pregnancy out come?
2.  Does intervention improve out come?
3. Is such intervention cost effective?
4. What is the optimum screening / diagnostic test?
Successful screening test requires that the condition should be prevalent in the 
target population, procedure should be cost effective and the treatment improves the 
prognosis.  20-30% of untreated GDM women give birth to infant >4 kg. 6-20% has 
increased pregnancy induced hypertension in pregnancies marked as GDM.
The principle benefit of successful screening for GDM is the ability to identify 
group  of  women  at  risk  subsequently  developing  diabetes  mellitus.Such  woman 
successfully  targeted to modify life  style  and comply regular  follow up to aid early 
identification of diabetes mellitus.
All the recognized pregnancy complications of diabetes mellitus are exacerbated 
by  hyperglycemia,  hence  strict  attention  to  glycemic  control  periconceptionally  and 
through out pregnancy is required.
Because of heterogenous nature of pregnancy out come, the cost effectiveness of 
screening for GDM is low universal screening should be justified.
Overt diabetes with FBS >126 mg% according to ADA (2004) is used because 
data indicate the risk of retinopathy rises dramatically at this fasting level.
Women diagnosed to have GDM early in pregnancy are at high risk group (8). 
Murphy  and  colleagues  studied  to  avoid  glucometer  for
screening (9) 
Word  ‘gestational’ implies  that  diabetes  is  induced  by  pregnancy,  from 
exaggerated physiological changes in glucose metabolism or type 2 diabetes unmasked 
and discovered during pregnancy.
More  than  half  of  women  with  GDM  ultimately  develop  overt  diabetes  in 
ensuring 20 years and there is mounting evidence of large complications that include 
obesity and diabetes in their offspring.
Despite more than 30 years research there is no consensus regarding the optimal 
approach to screen for gestational diabetes mellitus.  For the definite diagnosis WHO 
1985 recommended 75 gm - 2 hr glucose tolerance test approach is used.
ADA (1999 a) has concluded that fasting hyperglycemia > 105 mg / dl increases 
risk of fetal death during last 4-8 weeks of gestation.
GDM have babies with increased fat deposition in back and shoulder leading to 
shoulder dystocia 3% (Magee and collegues) – and 4% GDM babies require i.v. glucose 
therapy for hypoglycemia. Neonatal hypoglycemia is defined when the blood glucose is 
< 45 mg / dl (10).
Although  uncomplicated  GDM  with  less  severity  increases  risk  of  fetal 
macrosomia,  neonatal  hypoglycemia,  jaundice,  polycyethemia,  hypocalcemia  may 
complicate GDM as well.
The true definition of hyperglycemia in pregnancy judged by the internationally 
acceptable 75 gm oral glucose tolerance test ‘awaits the result of large hyperglycemia 
and adverse pregnancy out come study (HAPO) (11).
Study conducted  on 4300 pregnant  women involving over  90  PHC and some 
private practitioners. It used one step procedure where only one blood sample have to be 
collected. It was found that 17% had GDM, study was conducted in all 3 trimester, early 
screening could go a long way in avoiding the dreaded complications of disorder.
The merit of this study is to compare the well accepted methods for diagnosis of 
GDM and  determine  the  best  method.  One  step  procedure  may  be  better  tolerated 
compared to 2 step procedure with respect to number of visits,  amount of drink and 
length of testing. Diagnosis by single test may avoid unnecessary delay in initiation of 
therapy and still identify these patients at risk for type 2 diabetes mellitus.
AIM OF STUDY
1.  To know the Incidence of GDM in our population.
2. Effectiveness of screening using single step procedure with 75 gm oral glucose.
3. To substantiate that universal screening is necessary in our population.
4. To analyse maternal and perinatal outcome in GTT positive and GTT negative 
patients.
MATERIALS AND METHODS
Prospective Study was done in, Kilpauk Medical College and Hospital, having 
deliveries of about 7500 to 8500 per annum, with daily antenatal patient attendance of 
120 – 130.
Randomly  selected  500 patients  in  gestational  age  14  –  36  weeks  by  clinical 
examination height, 1st trimester weight, general examination, obstetric examination of 
the patient, from June 2006 to August 2007 of 14 months duration.  These women were 
booked for delivery at KMCH.
A detailed  history  was  taken  regarding family  history,  past  history  and about 
current pregnancy. Selected patients for study was given dates to come in fasting state, 
FBS taken and 75 gm oral glucose was given in 200 ml of water. 2 hours later blood 
sugar was taken.
Glucose estimation done at diabetology department. Test sample was collected in 
glass tube with sodium fluoride for inhibiting glucose utilization and EDTA for anti 
coagulation.
Criteria for diagnosing GDM by WHO criteria of 2 hours blood sugar level 140 
mg % and above is to be diagnosed as GDM. Patients diagnosed as GDM were closely 
monitored with frequent antenatal checkup. Intrapartum monitoring, mode of delivery, 
details regarding neonatal complications were observed.
INCLUSION CRITERIA
 All pregnant women irrespective of age and parity.
 Gestational age between 14 and36 weeks.
EXCLUSION CRITERIA
 Known Diabetes mellitus.
 Gestational age more than 36 weeks and less than 14 weeks
 Patients on drugs steroids, Calcium Channel blockers, Thiazides
RESULTS AND ANALYSIS
Table 1: Incidence:
GDM No. of Patients Percentage
Yes 33 6.60
No 467 93.40
500 100%
2 hr blood glucose ≥ 140 mg%, incidence is 6.6%
Blood glucose ≥ 130 mg%, incidences is 8%
Blood glucose ≥ 120 mg%, incidence is 10.8%
Table 2: Age Distribution :
S.No. Age(yrs) Non GDM GDM Percentage GDM
1
2
3
4
5
< 20  
21-25
26-30
31-35
36-40
86
252
93
30
6
1
12
12
6
2
3.04
36.36
36.36
18.18
6.06
467 33 100%
Mean Age 24.32 years, less than 20 years the Incidence is 3.04%, 72.72% is in between 
21-30 years.
Table 3: Body Mass Index
BMI Non GDM GDM Percentage
Normal < 25
Over Weight 25-30
Obesity > 30
332
114
21
12
16
5
36.36
48.48
15.16
467 33 100%
Mean BMI is 23.52
GDM women with  Obesity is 15.16% and over weight is 48.48%.
Table 4: Family History of DM
Family H/o Non GDM GDM Percentage GDM
No
Yes
Pr. GDM
432
35
0
22
7
4
66.67
21.21
12.12
467 33 100%
In GDM women ,  no family History of  Diabetes  in  66.67%, with family history in 
21.21%.
Table 5: Obstetric Score
Gravida GDM Non GDM Percentage GDM
Primi
G2
G3
G4
G5
G6
4
7
13
3
4
2
190
179
59
30
9
0
12.12
21.21
39.39
9.09
12.12
6.06
33 467 100%
Abortions GDM Non GDM Percentage GDM
A0
A1
A2
A3
A4
22
8
1
2
0
363
73
22
8
1
66.67
24.24
3.03
6.06
0
33 467 100%
GDM women 12.12% were primi, 60.6% were Gravida 2 and Gravida 3, Nulli para were 
48.48%, no fetal wastage in 66.67%.
Table 6: Gestational Age
S.No. GA in weeks Non GDM GDM Percentage GDM
1
2
3
4
5
14-20
21-24
25-28
29-32
33-36
96
133
142
72
24
3
9
1
7
8
9.09
27.27
3.03
36.36
24.24
467 33 100%
In GDM patients GA less than 20 weeks 9.09%, between 29-32 weeks 36.36%, GA upto 
36 weeks is 24.24%
Table 7: Fasting blood sugar
FBS GDM Non GDM Percentage GDM
< 95 mg
96-125
>125
6
20
7
415
51
1
18.18
60.61
21.21
33 467 100%
Fasting blood sugar: Mean 115 mg%.  Fasting Blood Sugar up to 125 mg% is 78.79%, 
more than 125mg% is 21.21%.
Table 8: Post Prandial Blood Glucose - GDM
PPBS NO Percentage
< 160 mg 
161-200 mg
> 200 mg
17
9
6
53.13
28.13
18.74
33 100%
 
PPBS:  Mean 178 mg% PPBS more than 200mg% is 18.74% and Blood Sugar Less than 
160 mg% is 53.13%.
Table 9: Risk Factors
Risk Factors No. of Patients Percentage
No
PIH
Hydrammios
Pr. CHD
Pr. NTD
Pr. Twin  
22
3
3
1
1
3
66.67
9.09
9.09
3.03
3.03
9.09
33 100%
With no risk factors in 66.67% of GDM Women, previous IUD 6.06%, previous Birth 
Weight More than 4Kg is Nill, Previous Congenital Anomaly is 6.06%.
Table 10: Mode of Treatment
Mode of Treatment No Percentage
Meal Plan 
Insulin  
28
5
84.85
15.15
33 100%
28 GDM women were started on meal plan, 5 patients were started on insulin.  27.27% 
of patients started with MNT had been supported with insulin later. 
Table 11: GA at termination of Pregnancy
GA (weeks) No Percentage
Undelivered
32
36
37
38
39
9
1
2
4
11
6
27
3
6
11
33
20
33 100%
33% GDM women were terminated at 38 weeks of gestational age, 20% were delivered 
at 39 weeks. 3 had pre-term delivery.
Table 12:  Mode of Delivery
27% were delivered by labour natural, 27% by Caesarian section, 15.50% by Repeat 
Caesarian.
Table 13: GTT negative patients
Mode of Delivery Number
Lab: Natural 320
Forceps 12
LSCS 80
Undelivered 15
Lost follow up 30
Total 467
Table 14: Indication for LSCS - GDM
Indication No Percentage
Breech
GDM with mobile head 
CPD II0
Fetal Distress
PPROM 
Rpt.  LSCS 
1
4
1
2
1
5
7
28.5
7
15
7
35.5
14 100
7% had been operated for CPD II°, 15% had LSCS for Fetal Distress, 35.5% had Rpt. 
LSCS, emergency LSCS 28%, elective LSCS 72%.
Table 15: Birth Weight
B. Weight 
(Kgs.)
Non GDM GDM Percentage
0< 2.5
2.6 – 3
3.1 – 3.5
> 3.6 – 3.9
55
147
167
86
12
9
3
5
8
8
27
9.09
15.15
24.24
24.24
412 33 100%
24.24% had birth weight between 3.1 to 3.5 kg, 24.24% had weight more than 3.6 Kg. In 
GDM patients no macrosomia noted in this study.
Table 16: NICU Care
Neonatal complications Non GDM GDM
Hypoglycemia
Hypocalcemia
Hyperbilirubinemia
Macrosomia
Congenital anomaly
Respiratory distress
10
0
26
2
0
16
3
0
6
0
0
2
Three babies of GDM mother had features of hypoglycemia, 2 babies had blood sugar 
less than 25 mg, 1 has blood sugar less than 30 mg.
Table 17: BMI and GDM
BMI GDM Non GDM Total 
Non Obese 
Obese
12
21
333
134
345
155
Total  33 467 500
Obese women are more prone to GDM rather than non obese women.
P: 0.000027
Table 18: Elderly mother and GDM
Age GDM Non GDM Total
< 30 Yrs
> 30 Yrs
23
10
431
36
454
46
Total 33 467 500
 
Elderly mother greater than 30 years are more prone to GDM than women less than 30 
Years. P – 0.000014.
Table 19: Birth Weight GDM and Non GDM
Number Mean SD 95% of CLLCL UCL
GDM 24 3.28 kg 0.54 3.05 3.51
Non GDM 412 2.70 kg 0.48 2.66 2.75
P = 0.000.  GDM babies mean 3.28 kg.
   Non GDM babies mean 2.7 kg.
DISCUSSION
The prevalence of GDM varies in direct proportion to the prevalence of NIDDM 
in a given population or ethnic group.  Prevalence of GDM in United States is 2 – 5%, 
less than 1% is noted in China, Srilanka, Italian Women.
 Highest was found in Pima / Papago and India 14 – 22%.study conducted with 
891 patients, 16.2% is the incidence in North Chennai. In South Chennai 15% is the 
incidence of GDM in the study conducted with 1002 patients (12).
In some population diabetes was undiagnosed prior to the study. IGT was mostly 
overlooked in routine clinical practice. Dooley et al demonstrated that race as well as 
maternal  age  and  degree  of  obesity  must  be  taken  into  account  in  comparing  the 
prevalence of GDM in different populations.   Influence of race and disease predicts 
prevalence and perinatal outcome (13).Incidence of GDM is 6.6% in this study.
Over the next 2-3 decades there will be 80 million reproductive age women with 
Diabetes  in  world,  of  this  20  millions  will  be  in  India  alone,  creating  potential  for 
extremely  high  rates  of  maternal  and  infant
mortality (14).
Number  of  prospective  and  retrospective  studies  have  substantiated  that  the 
frequency of adverse fetal out come increase with 2 hour PG >   120 mg% and taking 
care of women has resulted in better fetal outcome. Incidence of GDM is 10.8%, if the 
cut  off  value  is  > 120  mg%  in  this
study (15). 
Xiong  et  al  Studied  that  incidence  of  GDM is  22.4% compared  to  10.3% in 
women more than 35 years (16).  In this study 38% GDM women are more than 30 
years,  out  of  33  women  10  were  more  than  30  years,  
P < 0.000014.  Boet et al proved that prevalence of GDM increases from         1.5 /1000 
deliveries to 4.2/1000 for women aged more than 30 years (17). 
Jimenez et al 41.8 % were older than 30 years of age, 26.2% were younger than 
25 of age. The positive predictive value of the screening test for a single risk factor was 
22.9 (18).  Age adjusted OR (95% CI) for women with Multigravida or more deliveries 
compared with primi (19). Among GDM women multigravida more than 3, accounts for 
66% in the study.
Obesity more than 91kg is detected with 15.8% of GDM compared with 7.3% of 
normal groups (20).  Koustal et al, women with previous GDM had higher BMI 26.4 to 
23.8 and waist hip ratio 0.8 in GDM compared to normal 0.77 (21). In this study out of 
33  patients  21  were  obese,  
P < 0.000027.
Compared  with  controls  GDM  patients  showed  higher  prevalence  of  PCOS, 
greater clinical and biochemical evidence of hyperandrogenism and insulin resistance 
and higher prevalence of PIH. GDM developed in 20% of PCOS compared to 8.9% in 
controls  (22).  Out  of  33  GDM women  6.06% had  been  treated  for  PCOS.   GDM 
accounts 30.6 %  in women whose mother has GDM versus 3.5% in controls (23). In 
this study 66.67% GDM positive women were with out family history of diabetes.
Recurrence of  GDM is  35.6%.  Multivariate  models  shows that   infants  birth 
weight in index pregnancy and maternal pre pregnancy weight gain before subsequent 
pregnancy,  were  predictive  of  recurrent  GDM (24).12.12% is  the recurrence  rate  of 
GDM in this study.
Higher incidence of GDM rate in triplets than the reduction group 22.3 Vs 5.8% 
(25).  Recurrence rate of GDM 35 to 85% is influenced by parity, BMI, early diagnosis 
of GDM, Insulin requirements, weight gain and by the interval between the pregnancy.
High risk individual requires both initial screening and repeated testing during and 
after pregnancy (26).  Christine C et al compared the incidence of GDM in twin with 
that of triplets mother with triplets, 30 was more at a risk of developing GDM P < 0.05. 
Family history and risk factors was not contributing (27). 9.09% of GDM patients had 
previous twin pregnancy in the study.
Pregnancy total weight gain outside the institute of medium recommendation and 
rates of maternal weight gain are associated with Neonatal complications–Macrosomia, 
hypoglycemia and hyperbilirubinemia than those women whose weight gain was in the 
recommended range (28).  The cummulative risk of developing type 2 DM for GDM 
patient was 25.8% at 15 years post diagnosis (29).
Canadian  Diabetic  Association  study  of  100  gm Vs  75gm reference  study  of 
58000 patients completed in 2004. Study concludes that single step screening is better 
tolerated than other methods. 
 Gultonen  and  Terano  (1993)  reported  that  cases  of  PIH  and  pre  eclampsia 
contributed to the incidence two times more common among GDM than controls (30). 
9.09% GDM women has been associated with severe PIH in this study.
Jacobson reported incidence of polyhydramnios is 2% in GDM compared to 0.5 – 
0.7%  of  hydramnios  in  control  group.   In  this  study  9.90%  GDM  women  had 
hydramnios.  Increase caesarian rate was significantly higher in gestational diabetes and 
overt diabetes than in control group (31).
O Sullivans (1982) have shown that 50% of all GDM will develop impaired GTT 
or  NIDDM  with  in  10  years  of  their  index  pregnancy.  Pregnancy  may  disclose 
intolerance without clinical symptoms, pre disposed women with good diabetic control 
however  decrease  the  incidence  of  congenital  malformation  even  in  patients  with 
vascular complications (32). 
According to coustan et al 1989 universal screening is more cost effective than 
selective  screening for  gestational  diabetes  in  ethnic  group population.  Diagnosis  of 
GDM by OGTT based on initial GCT Screaning leaves 21.5% undiagnosed. Single step 
75gm oral  glucose  serves  both  screening  and  diagnostic  procedure  (33).  Out  of  23 
delivered women 15 turned up for  follow up, OGTT is within normal limits after  6 
weeks.  
“A short term intensive care gives a long term pay off in the primary prevention 
of  obesity,  IGT  and  diabetes  in  the  offspring,  as  the  preventive  measures  starts  in 
intrauterine life.”
SUMMARY
 Incidence of GDM is 6.06%.
 Mean age group is 24years.
 Elderly women > 30 years are more Prone to GDM.
P < 0.000014.
 Obese women with BMI > 25 were prone to GDM then non obese women, 
P < 0.000027.
 66.67% GDM diagnosed women has no family history of diabetes. 
  60.6% were multigravida, no fetal wastage in 66.67%.
 9.09% diagnosed to have GDM in less than 20 weeks of gestational age.
 66.67% had no associated risk factor.
 21.21% has FBS > than 125mg% and 18.75% had PPBS more than 200mg
%.
 84.85% of GDM patients had treated with meal plan.
 27.27% among meal plane group has been switched over to insulin after 
MNT.
CONCLUSION
 Incidence of GDM is 6.6% in the study conducted.
 Universal  screening  by  single  step  procedure  is  convenient,  economical  and 
suitable alternative screening test with out sacrificing these sensitivity expected 
for screening test.
 Thereby early  detection and effective  management  to  maintain  optimal  blood 
glucose concentration will reduce perinatal mortality and morbidity and adverse 
effect for the mother in future.
 Despite years of meticulous study, paucity of information still exits regarding the 
optimal maternal glucose levels that should be aimed for in order to reduce the 
embryonic,  fetal  and perinatal  morbidity  and yet  not  cause any harm to intra 
uterine development.
 The goal is to encourage early referral of both pre gestational and gestational 
diabetic women so that the tight glycemic control will be instituted at the proper 
time in order to prevent maternal hyperglycemia complications.
 The key finding here is that the risk of overweight and obese children rises in step 
with  higher  levels  of  blood sugar  during pregnancy.   By treating Gestational 
Diabetes, future risk of children becoming overweight, obese, PCOS, Diabetes 
drops considerably.  
 To  help  expectant  women  to  enjoy  the  arrival  of  their  sweet  ones,  the 
Government  of  Tamil  Nadu  has  planned  the  GDM  screening  project  in  all 
Government Hospitals from March 08, 2007 (GO No. 356 Health and Family 
welfare), on Women’s Day since “Women Health is Nation’s Wealth” in order to 
ensure the early diagnosis of GDM, to reduce infant mortality rate in the state.
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PROFORMA
Perform – Screening for GDM
S.No : Date :
A.N. No : Height :
Unit : Weight :
Parity : BMI       :
LMP :
EDD :
Name and Address : Age :
MD Since : Consanguinity :
Family history 
PCOS 
Menstrual H/O :
Present Pregnancy:
 Abortions 
 Congenital Anomaly
 Preterm Delivery 
 Unexplained still birth 
 Unexplained neonatal death 
 Big babies 
 Polyhydramnios 
Obs H / O – GA   Type of Delivery       Baby Wt              Sex           GC
Baby – Whether Admitted in NICU
O / E
INV:
Date / GA USG
Time 
FBS 
2 Hrs PPBS
Results 
Treatment Plan:
Follow up:
 Mode of Delivery
 Associated Cpl
Foetal Outcome 
Apgar
Weight 
Associated Complications
Neonatal Stay
After Peurparium – 6 Weeks OGTT
ABBREVIATIONS
BMI - Body mass index
CHD  - Congenital Heart disease
CMV - Cyto Megalo virus
F dis - Fetal Distress
F - Forceps
F+, M+       -        Father, mother diabetic 
FBS/FBG - Fasting blood sugar/glucose
GA - Gestational age
GDM / DM- Gestational diabetes mellitus / Diabetes mellitus
IGT - Impaired glucose tolerance
IR-S - Insulin Receptor Substrate
IUD - Intra uterine death
LN - Labor natural
LSCS /CS - Lower segment caesarian section / caesarian section
MNT - Medical nutrition therapy
NIDDM - Non insulin dependent diabetes mellitus
NTD - Neural tube defect
OGCT - Oral glucose challenge test
OGTT - Oral glucose tolerance test
PCOS - Polycystic ovarian syndrome
PIH - Pregnancy induced hypertension
PPBS - Post prandial blood sugar
PPROM - Preterm premature rupture of membranes
Pr / Rpt      -        Previous / repeat
